•
IO
IOBT
IO Biotech, Inc. Common Stock
polygonPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
37.10M
Volume
36.58M
52W High
$2.79
52W Low
$0.21
Open
$0.47
Prev Close
$0.52
Day Range
0.21 - 0.50
About IO Biotech, Inc. Common Stock
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
Latest News
IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
GlobeNewswire Inc.•Nov 7
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
Benzinga•Oct 27
Melanoma Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
GlobeNewswire Inc.•Oct 14
Nasdaq Jumps 150 Points; US Pending Home Sales Rise
Benzinga•Sep 29
TGF-β Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
GlobeNewswire Inc.•Sep 23
Untreated Metastatic or Unresectable Melanoma Clinical Trial Pipeline Expands as 10+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsight
GlobeNewswire Inc.•Aug 26
IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025
GlobeNewswire Inc.•Apr 26
IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference
GlobeNewswire Inc.•Feb 23